9 completed, 2 active not recruiting, 2 recruiting, 1 not yet recruiting. 14 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 9, Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow N,N-Dimethyltryptamine: new trials by email Literature Review of N,N-Dimethyltryptamine trials Research Report on N,N-Dimethyltryptamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neural Effects of Intravenous N,N-dimethyltryptamine (DMT) N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg) - Healthy Participants Study | Phase 1 | Not yet recruiting | Jon Dean | 20 | 2026-09-01 | 2026-07-09 |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Recruiting | Yale University | 63 | 2025-08-04 | 2026-09-10 |
| Investigation of Psychedelic Effects in Psychoactive Substances Placebo, Psilocybin, Ketamine - Psychedelic Effects in Healthy Volunteers | Phase 1 | Recruiting | Johns Hopkins University | 50 | 2025-02-05 | 2026-02-23 |
| Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study) N,N-Dimethyltryptamine (5mg), N,N-Dimethyltryptamine (10mg), N,N-Dimethyltryptamine (15mg) - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 36 | 2024-06-12 | 2025-04-11 |
| Molecular Imaging Study of Harmine/DMT: a Basic Research Approach N,N-dimethyltryptamine (DMT) + harmine, Placebo - Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine | Phase 1 | Completed | Insel Gruppe AG, University Hospital Bern | 17 | 2024-01-22 | 2025-03-19 |
| Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects Dimethyltryptamin (DMT) & Harmine - Healthy | Phase 1 | Completed | Reconnect Labs | 16 | 2023-05-05 | 2023-11-02 |
| Safety and Tolerability of DMT in Healthy Adults N,N-Dimethyltryptamine, Placebo - Safety Issues, Healthy Volunteers | Phase 1 | Completed | Universidade Federal do Rio Grande do Norte | 25 | 2023-04-26 | 2023-10-11 |
| Single and Repeat Doses of DMT in Healthy Subjects N,N-Dimethyltryptamine, Placebo - Stroke | Phase 1 | Active not recruiting | Algernon Pharmaceuticals | 60 | 2023-01-13 | 2025-01-28 |
| SPL026 With or Without SSRIs in Participants With MDD SPL026 - Major Depressive Disorder | Phase 1 | Completed | Small Pharma Ltd | 18 | 2022-12-13 | 2024-06-14 |
| Acute Dose-dependent Effects of DMT in Healthy Subjects N,N-Dimethyltryptamine (54 mg), N,N-Dimethyltryptamine (108 mg), N,N-Dimethyltryptamine (162 mg) - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 24 | 2022-11-15 | 2024-04-25 |
| Clinical Study of DMT in Healthy Adults N,N-Dimethyltryptamine - Healthy Volunteers | Phase 1 | Completed | Biomind Labs Inc. | 27 | 2022-06-01 | 2023-02-15 |
| Effects of Dimethyltryptamine in Healthy Subjects Dimethyltryptamine (DMT), Saline - Healthy | Phase 1 | Completed | University Hospital, Basel, Switzerland | 31 | 2021-06-18 | 2022-10-12 |
| Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT) - Major Depressive Disorder, Depression | Phase 1 | Active not recruiting | Yale University | 30 | 2021-03-17 | 2025-08-03 |
| SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients SPL026, Placebo - Major Depressive Disorder | Phase 1 / Phase 2 | Completed | Small Pharma Ltd | 66 | 2021-02-04 | 2024-03-27 |
Depressive Disorder, Major (3) · Depression (2) · Alcohol Drinking (1) · Alcohol-Related Disorders (1) · Alcoholism (1) · Stroke (1)
University Hospital, Basel, Switzerland (3) · Small Pharma Ltd (2) · Yale University (2) · Algernon Pharmaceuticals (1) · Biomind Labs Inc. (1) · Insel Gruppe AG, University Hospital Bern (1) · Johns Hopkins University (1) · Jon Dean (1) · Reconnect Labs (1) · Universidade Federal do Rio Grande do Norte (1)
Switzerland (5) · United States (4) · Brazil (2) · United Kingdom (2) · Netherlands (1)
Fabian Devlin, MD (2) · Anahita Bassir Nia, MD (1) · David Erritzoe, MD (1) · Draulio B. Araujo, Ph.D (1) · Erich Seifritz, Prof (1) · Frederick Barrett, Ph.D. (1) · Gabriel Jacobs, MD, PhD (1) · Jon Dean, PhD (1) · Malcolm Boyce, MD (1) · Matthias E Liechti, MD (1) · Matthias E Liechti, Prof. Dr. MD (1) · Neel Bhatt, MD (1) · Paul K Cumming, PhD (1)
PMID 40484114, PMID 37086340, PMID 37221177, PMID 38274414, PMID 40356576, PMID 40375477, PMID 40532423, PMID 41699126, PMID 42220002, PMID 42649324
R21AA030649 (1)